COVID-19 Update 13: Randomized Controlled Trial of Hydroxychloroquine (Chen et al., Wuhan, China)
羟氯喹的随机对照试验（Chen等，中国武汉）
2月28日起，武汉人民？医院进行的一项随机临床试验，遵循了很好的科研原则。142名确诊病人，选样条件为，大于18岁，阳性，确诊患有肺炎，氧饱和度大于93%，都选取轻症患者，80名病人被排除，剩余62人分成两组，性别，年龄大体相当，一组每日400毫克羟氯喹，另外31为病人为对照组，进行其他方法治疗。病人和医生都不知道实情，每天测量3次体温，和检查咳嗽状况，第一天和第六天做CT检查。
使用羟氯喹组发烧，咳嗽的恢复时间短于对照组，分别为2天对3天，对照组有4人转为重症，羟氯喹组无人转重症，羟氯喹组有两人出现过敏反应：一人出疹子，一人头疼。CT检查发现，羟氯喹组81%有所改进，对照组为55%。
这是个好消息。我们期待听到有关最近启动的世界卫生组织大型试验的结果，该试验还评估了氯喹（以及其他药物）。
Finally, we have a randomized clinical trial assessing the efficacy of hydroxychloroquine for the treatment of mild cases of COVID-19. The trial was performed in Remnin Hospital in Wuhan and seems to have adhered to good scientific research principles. Also, their chosen outcomes (recovery times and CT findings) are much more relevant as compared to PCR of nasopharyngeal swabs. This is great news. We are looking forward to hearing about the results of the recently launched WHO mega-trial, which also assesses chloroquine (among other drugs).
